JP2025508073A - ＴＧＦ－β抗体 - Google Patents

ＴＧＦ－β抗体 Download PDF

Info

Publication number
JP2025508073A
JP2025508073A JP2024553443A JP2024553443A JP2025508073A JP 2025508073 A JP2025508073 A JP 2025508073A JP 2024553443 A JP2024553443 A JP 2024553443A JP 2024553443 A JP2024553443 A JP 2024553443A JP 2025508073 A JP2025508073 A JP 2025508073A
Authority
JP
Japan
Prior art keywords
seq
tgf
amino acid
antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024553443A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508073A5 (enExample
Inventor
マリエン，ローレ
ベック，ジッテ デ
ルーカス，ソフィー
ランバート，ファニー
ダー ウォニング，セバスチャン ポール ヴァン
リエナール，ステファニー
Original Assignee
ウニベルシテ カソリーク デ ルーベン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウニベルシテ カソリーク デ ルーベン filed Critical ウニベルシテ カソリーク デ ルーベン
Publication of JP2025508073A publication Critical patent/JP2025508073A/ja
Publication of JP2025508073A5 publication Critical patent/JP2025508073A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2024553443A 2022-03-09 2023-03-09 ＴＧＦ－β抗体 Pending JP2025508073A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2203269.2A GB202203269D0 (en) 2022-03-09 2022-03-09 TGF-Beta antibodies
GB2203269.2 2022-03-09
PCT/EP2023/056082 WO2023170241A1 (en) 2022-03-09 2023-03-09 TGF-β ANTIBODIES

Publications (2)

Publication Number Publication Date
JP2025508073A true JP2025508073A (ja) 2025-03-21
JP2025508073A5 JP2025508073A5 (enExample) 2026-03-13

Family

ID=81175458

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024553443A Pending JP2025508073A (ja) 2022-03-09 2023-03-09 ＴＧＦ－β抗体

Country Status (9)

Country Link
US (1) US20250188161A1 (enExample)
EP (1) EP4490186A1 (enExample)
JP (1) JP2025508073A (enExample)
CN (1) CN119173533A (enExample)
AU (1) AU2023229972A1 (enExample)
CA (1) CA3245104A1 (enExample)
GB (1) GB202203269D0 (enExample)
IL (1) IL315033A (enExample)
WO (2) WO2023170241A1 (enExample)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
RS61778B1 (sr) * 2013-05-06 2021-06-30 Scholar Rock Inc Kompozicije i postupci za modulaciju faktora rasta
ES2860952T3 (es) 2013-08-01 2021-10-05 Univ Catholique Louvain Proteína anti-garp y usos de la misma
EP3139957A4 (en) * 2014-05-06 2018-04-25 Scholar Rock, Inc. Compositions and methods for growth factor modulation
WO2016125017A1 (en) 2015-02-03 2016-08-11 Universite Catholique De Louvain Anti-garp protein and uses thereof
AU2018387829B2 (en) 2017-12-22 2024-12-19 Argenx Bvba Bispecific antigen binding construct

Also Published As

Publication number Publication date
EP4490186A1 (en) 2025-01-15
WO2023170242A1 (en) 2023-09-14
IL315033A (en) 2024-10-01
WO2023170241A1 (en) 2023-09-14
GB202203269D0 (en) 2022-04-20
CN119173533A (zh) 2024-12-20
AU2023229972A1 (en) 2024-09-12
CA3245104A1 (en) 2023-09-14
US20250188161A1 (en) 2025-06-12

Similar Documents

Publication Publication Date Title
JP7679430B2 (ja) Ｇｐｒｃ５ｄに結合する抗体
US11242404B2 (en) Antibodies against signal-regulatory protein alpha and methods of use
US20240067734A1 (en) Antibodies binding to NKG2D
US20220411491A1 (en) Antibodies binding to gprc5d
JP7366897B2 (ja) 抗ｔｉｇｉｔ抗体
CN112969714B (zh) 抗cd40抗体、其抗原结合片段及其医药用途
CN114828965B (zh) 与hla-a2/mage-a4结合的抗体
TW201936641A (zh) 結合gprc5d之抗體
CN111526888A (zh) 抗tigit抗体及其作为治疗和诊断的用途
WO2019152715A1 (en) Anti-ms4a4a antibodies and methods of use thereof
CN113583128A (zh) 抗garp蛋白及其用途
TW201930356A (zh) 結合hla-a2/wt1之抗體
WO2018219327A1 (zh) 抗cd40抗体、其抗原结合片段及其医药用途
KR20210113282A (ko) 항-tigit 항체
CN116375869A (zh) TGF-β-RII结合蛋白质
JP2022505144A (ja) Ｈｅｒ２ ｓ３１０ｆ特異的な抗原結合分子
CA3156080A1 (en) LIF SPECIFIC BINDING MOLECULE AND ITS USE
KR20260051068A (ko) Enpp3 및 cd3 결합제 및 이의 사용 방법
US20250188161A1 (en) TGF-ß ANTIBODIES
WO2021180676A1 (en) MuSK AGONIST ANTIBODY
CN121969650A (zh) Ror1抗体的糖工程化形式和使用方法
HK40061355A (en) Antibodies binding to gprc5d
CN115698078A (zh) 人源化抗人cd89抗体及其用途
HK40034438A (zh) 抗ms4a4a抗体及其使用方法
EA045372B1 (ru) Анти-tigit антитела

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260305

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260305